Eugen Stermetz
Directeur Financier/CFO chez SWISSCOM AG
Fortune : 96 072 $ au 30/04/2024
Profil
Eugen Stermetz est actuellement directeur financier de Swisscom AG. Dans sa carrière antérieure, il a été directeur financier chez FIBREX Medical, Inc, directeur financier chez F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH, directeur financier chez igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH, directeur financier chez SVOX AG et consultant en gestion chez Boston Consulting Group Service GmbH. Eugen Stermetz a obtenu un doctorat de l'université de Vienne et un diplôme de premier cycle de l'université de Saint-Gall.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SWISSCOM AG
0,00% | 31/12/2022 | 175 ( 0,00% ) | 96 072 $ | 30/04/2024 |
Postes actifs de Eugen Stermetz
| Sociétés | Poste | Début |
|---|---|---|
| SWISSCOM AG | Directeur Financier/CFO | 01/03/2021 |
Swisscom (Schweiz) AG
 Swisscom (Schweiz) AG Major TelecommunicationsCommunications Swisscom (Schweiz) AG engages in the provision of telecommunications, broadcasting, and information technology services. It also specializes in the marketing of products for computer systems, including the design, development, and licensing of software. The company was founded on December 9, 1997 and is headquartered in Bern, Switzerland. | Directeur/Membre du Conseil | - |
| Pensionskasse comPlan | Directeur/Membre du Conseil | - |
Fastweb SpA
 Fastweb SpA Major TelecommunicationsCommunications Fastweb SpA engages in the provision of solutions for internet connectivity. The firm offers a wide range of voice and data services, fixed communication, and mobile to households and businesses. It also constructs fiber optic network infrastructure and adopts internet protocol for voice, data, and video transmission. The company was founded by Silvio Scaglia in September 1999 and is headquartered in Milan, Italy. | Directeur/Membre du Conseil | - |
Anciens postes connus de Eugen Stermetz
| Sociétés | Poste | Fin |
|---|---|---|
SVOX AG
 SVOX AG Packaged SoftwareTechnology Services SVOX AG develops speech, voice and language output solutions and related equipment. The company was founded by Volker P. Jantzen, Alexander E. Fries and Bettina Hein in April 2000 and is headquartered in Zurich, Switzerland. | Directeur Financier/CFO | 01/01/2011 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH
 F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH Medical SpecialtiesHealth Technology F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria. | Directeur Financier/CFO | 01/01/2008 |
| Igeneon AG | Directeur Financier/CFO | 01/01/2005 |
Boston Consulting Group Service GmbH
 Boston Consulting Group Service GmbH Miscellaneous Commercial ServicesCommercial Services Part of BCG Holding Group SCS, Boston Consulting Group Service GmbH is a German company that provides management consulting services. The company is based in Munich, Germany. | Corporate Officer/Principal | - |
FIBREX Medical, Inc.
 FIBREX Medical, Inc. Miscellaneous Commercial ServicesCommercial Services FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases. The company aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction. | Directeur Financier/CFO | - |
Formation de Eugen Stermetz
| University of Vienna | Doctorate Degree |
| University of St. Gallen | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SWISSCOM AG | Communications |
| Entreprise privées | 9 |
|---|---|
igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH
 igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH BiotechnologyHealth Technology igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH develops biological products to treat cancer and other diseases. It focuses on cancer immunotherapies designed to prevent or delay the formation of metastases in cancer of epithelial origin, including colorectal, breast and lung cancer. Founded in 1999, the company is headquartered in Vienna, Austria. | Health Technology |
FIBREX Medical, Inc.
FIBREX Medical, Inc. Miscellaneous Commercial ServicesCommercial Services FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases. The company aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction. | Commercial Services |
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH Medical SpecialtiesHealth Technology F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria. | Health Technology |
SVOX AG
SVOX AG Packaged SoftwareTechnology Services SVOX AG develops speech, voice and language output solutions and related equipment. The company was founded by Volker P. Jantzen, Alexander E. Fries and Bettina Hein in April 2000 and is headquartered in Zurich, Switzerland. | Technology Services |
Boston Consulting Group Service GmbH
Boston Consulting Group Service GmbH Miscellaneous Commercial ServicesCommercial Services Part of BCG Holding Group SCS, Boston Consulting Group Service GmbH is a German company that provides management consulting services. The company is based in Munich, Germany. | Commercial Services |
Swisscom (Schweiz) AG
Swisscom (Schweiz) AG Major TelecommunicationsCommunications Swisscom (Schweiz) AG engages in the provision of telecommunications, broadcasting, and information technology services. It also specializes in the marketing of products for computer systems, including the design, development, and licensing of software. The company was founded on December 9, 1997 and is headquartered in Bern, Switzerland. | Communications |
| Pensionskasse comPlan | |
| Igeneon AG | |
Fastweb SpA
Fastweb SpA Major TelecommunicationsCommunications Fastweb SpA engages in the provision of solutions for internet connectivity. The firm offers a wide range of voice and data services, fixed communication, and mobile to households and businesses. It also constructs fiber optic network infrastructure and adopts internet protocol for voice, data, and video transmission. The company was founded by Silvio Scaglia in September 1999 and is headquartered in Milan, Italy. | Communications |